377O A pooled analysis of trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-positive (HER2+) metastatic breast cancer (mBC) with brain metastases (BMs) from DESTINY-Breast (DB) -01, -02, and -03
S.A. Hurvitz(University of California, Los Angeles), Shanu Modi(Memorial Sloan Kettering Cancer Center), Wěi Li(Jilin University), Y.H. Park(Samsung Medical Center), Wei‐Pang Chung(National Cheng Kung University), S-B. Kim(Asan Medical Center), Javier Cortés, Toshinari Yamashita(Kanagawa Prefectural Hospital Organization), José Luiz Pedrini(Hospital Nossa Senhora da Conceição), S-A. Im(Seoul National University Hospital), L-M Tseng(Taipei Veterans General Hospital), Nadia Harbeck(Ludwig-Maximilians-Universität München), I. Krop(Yale Cancer Center), G. Curigliano(University of Milan), E. Mathias(Daiichi Sankyo (United States)), Jillian Cathcart(Daiichi Sankyo (United States)), A. Cagnazzo(Daiichi Sankyo (United States)), Shahid Ashfaque(Daiichi Sankyo (United States)), Anton Egorov(Daiichi Sankyo (United States)), Fabrice André(Institut Gustave Roussy)
Cited by 56Open Access